• Improving on "Natural" Rodent Antibodies
• 26 min
  1. The immunogenicity problem in antibody therapy

  • Prof. Herman Waldmann
• 32 min
  2. Antibodies by protein engineering

  • Prof. Sir Gregory Winter
• 60 min
  3. The generation of diversity in antibody genes

  • Prof. Michael Neuberger
• 51 min
  4. Innate immunity to retroelements by human AID/APOBEC3 proteins

  • Prof. Reuben Harris
• 36 min
  5. Fc receptors and antibody effector functions

  • Dr. Mike Clark
• 57 min
  6. Antibody engineering of Fc effector functions

  • Dr. Mike Clark
• 35 min
  7. Antibody engineering: beginnings to bispecifics and beyond

  • Dr. Ian Wilkinson
• Antibodies in Cancer Therapy
• 41 min
  8. Monoclonal antibodies and the ErbB system in human cancer

  • Prof. Mark Greene
• 71 min
  9. Checkpoint blockade in cancer immunotherapy

  • Prof. James Allison
• 45 min
  10. Monoclonal antibodies in haemato-oncology

  • Prof. Mark Cragg
• Diagnostic Antibodies
• 46 min
  11. Monitoring therapy with antibodies

  • Dr. Geoffrey Hale
• Cell Surface Glycoproteins on Cells of the Immune System
• 38 min
  12. Cell surface glycoproteins on cells of the immune system

  • Prof. Neil Barclay
• Antibodies as Immunosuppressants
• 29 min
  13. Monoclonal antibodies to induce therapeutic immunological tolerance

  • Prof. Herman Waldmann
• 29 min
  14. Antibodies to control or prevent type 1 diabetes

  • Dr. Robert Hilbrands
• 48 min
  15. Antibody therapy of multiple sclerosis

  • Dr. Alasdair Coles
  • Prof. Alastair Compston
• 42 min
  16. Monoclonal antibodies in the management of rheumatoid arthritis

  • Prof. John Isaacs
• 40 min
  17. Modern management of rheumatoid arthritis - with a focus on biologic therapies

  • Prof. John Isaacs
• 30 min
  18. Tolerance induction to clotting factors with monoclonal antibodies

  • Prof. Luis Graca
• Archived Lectures *These may not cover the latest advances in the field
• 26 min
  19. Alemtuzumab (Campath-1H) in therapy of CLL

  • Prof. Kanti Rai
• 71 min
  20. VEGF inhibitors for anti-angiogenic therapy

  • Prof. Kari Alitalo
  • Dr. Bronislaw Pytowski
• 26 min
  21. Human antibodies produced in mice

  • Dr. Marianne Bruggemann
• 52 min
  22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man

  • Prof. Christian Larsen
• 55 min
  23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity

  • Prof. Thomas Tedder
• 45 min
  24. Anti-IL-2 receptor antibodies as models for cancer therapy

  • Prof. Thomas Waldmann
• 58 min
  25. Anti TNF therapy in rheumatoid arthritis

  • Prof. Marc Feldmann
• 36 min
  26. Novel immunotherapeutic proteins: immunoligand

  • Prof. Terry Strom
• 21 min
  27. Diagnostic immunohistopathology

  • Prof. David Mason
• 56 min
  28. Antibodies in the control of type I diabetes

  • Prof. Lucienne Chatenoud
• 43 min
  29. The challenge of targeting toxins to tumors

  • Prof. Ben Seon
• 38 min
  30. Antibody depletion therapy in transplantation: implications for tolerance

  • Prof. Laurence Turka
• 36 min
  31. Antibodies as anti-virals

  • Prof. Dennis Burton

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Technical advances and science (1)
3. Technical advances and science (2)
4. Identification of proteins
5. Leucocyte-associated molecules
6. Principle of immunoperoxidase labeling
7. Immunoperoxidase labeling of tissue section
8. Immunohistological studies of human tissue
9. The first monoclonal anti-leucocyte antibodies
10. Destruction of epitopes on leucocyte
11. Paraffin-reactive monoclonal antibodies
12. Protein conformation and antigenicity (1)
13. Protein conformation and antigenicity (2)
14. Immunohistological markers: solid tumours (1)
15. Prostatic carcinoma
16. Seminoma
17. Mesothelioma
18. Melanoma
19. Carcinoid tumour
20. Markers of cell state (e.g. estrogen receptor)
21. Breast carcinoma (1)
22. Markers associated with genetic lesions
23. Breast carcinoma (2)
24. Carcinoma
25. Gastrointestinal stromal tumour (GIST)
26. Immunohistology of lymphoid neoplasms
27. Distinguishing lymphoma types
28. MALT lymphoma (1)
29. Proliferation, susceptibility to apoptosis markers
30. MALT lymphoma (2)
31. Markers of cell maturation state
32. Lymphoblastic lymphoma
33. Oncogenic proteins and neoplastic cell growth (1)
34. Oncogenic proteins in lymphoma (1)
35. Oncogenic proteins in lymphoma (2)
36. Anaplastic large cell lymphoma (1)
37. Anaplastic large cell lymphoma (2)
38. Immunostaining for anaplastic lymphoma kinase
39. Nucleophosmin expression patterns in AML
40. Nucleophosmin mutations in AML
41. Oncogenic proteins and neoplastic cell growth (2)
42. Markers for lymphoid neoplasms: summary (1)
43. Markers for lymphoid neoplasms: summary (2)
44. Diagnostic immunohistology - what's next?
45. Double immunostaining
46. Double immunoenzymatic labeling
47. Double enzyme vs. double fluorescence method
48. Anaplastic large cell lymphoma (1)
49. Anaplastic large cell lymphoma (2)
50. New labeling techniques and new antibodies
51. Rabbit and mouse monoclonal antibodies
52. New antibodies and molecular targets
53. Molecular targets of immunohistological studies
54. Transcription factors for immunohistology
55. Transcription factors for immunohistology: BCL6
56. Transcription factors for immunohistology: MUM1
57. Immunohistology molecules: PLCgamma1
58. Immunohistology signaling molecules: SLP76 (1)
59. Immunohistology signaling molecules: BCL6
60. Immunohistology signaling molecules: SLP76 (2)
61. Lyn kinase
62. Conclusions

Topics Covered

• Techniques for identification and immunocytochemical study of proteins
• Leucocyte-associated molecules
• Immunhistological labeling
• Immunohistological studies of human tissue
• The first monoclonal anti-leucocyte antibodies
• Paraffin reactive monoclonal antibodies
• Protein conformation and antigenicity
• Immunohistological markers for the study of solid tumors
• Carcinoma, seminoma, mesothelioma, melanoma and carcinoid tumors
• Immunohistological markers for the diagnosis of lymphoid neoplasms
• Anaplastic large cell lymphoma
• New labeling techniques
• New antibodies and molecular targets

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Immunology
• Methods

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on June 13, 2019

Financial Disclosures

• Prof. David Mason has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.